Corcept Therapeutics Officer Executes 10b5-1 Option Exercise and Sale

Insider Transaction Summary

• Reporting Person: Joseph Douglas Lyon, Chief Accounting & Technology Officer
• Issuer: Corcept Therapeutics Inc ($CORT)
• Transaction Dates: October 1, 2026 – October 2, 2026
• Nature of Transactions: Option exercise and simultaneous sale under a Rule 10b5-1 trading plan adopted on June 10, 2026.

Transaction Details

1. Option Exercises:

   • 810 options exercised at $13.56/share on October 1, 2026.
   • 3,357 options exercised at $13.56/share on October 2, 2026.
   • 5,833 options exercised at $19.26/share on October 2, 2026.
   • Total options exercised: 10,000 shares (Total exercise cost: $168,848.10).

2. Open Market Sales:

   • 2026-10-01: 810 shares sold at a weighted average price of $115.40 ($93,472.79).
   • 2026-10-02: 4,446 shares sold at a weighted average price of $115.70 ($514,388.86).
   • 2026-10-02: 4,744 shares sold at a weighted average price of $116.54 ($552,869.08).
   • Total shares sold: 10,000 shares for gross proceeds of $1,160,730.73 (weighted average price ~$116.07/share).

Holdings Following Transactions

• Direct holdings remain at 5,683 shares of Common Stock, which includes 1,243 unvested restricted stock awards scheduled to vest across multiple grant dates in late 2026 and 2027.
• The officer retains 44,167 vested/exercisable stock options expiring in February 2032.

Strategic Implications

Because all sales were executed under a pre-arranged Rule 10b5-1 plan adopted in June 2026 and represented matched option exercises with zero reduction in base non-derivative holdings, this transaction carries low informational signal regarding executive sentiment.